CLDN6 is another compelling target – being an oncofetal antigen, it is targeted by CAR T-cell therapies currently in early-phase trials (for ovarian cancer and other CLDN6+ solid tumors) (1). Here, CLDN6 is linked to ovarian carcinoma.